MOTILIUM Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

motilium

new pharmashop s.r.l. - domperidone - domperidone

MOTILIUM 30CPR RIV 10MG Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

motilium 30cpr riv 10mg

programmi sanit.integrati srl - domperidone - compresse rivestite - "10 mg compresse rivestite con film" 30 compresse

Darunavir Mylan Unione Europea - italiano - EMA (European Medicines Agency)

darunavir mylan

mylan pharmaceuticals limited - darunavir - infezioni da hiv - antivirali per uso sistemico - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):per il trattamento dell'infezione da hiv-1 in trattamento antiretrovirale (art) di pazienti adulti, compresi quelli che sono stati fortemente pre-trattati. per il trattamento dell'infezione da hiv-1 in pazienti pediatrici a partire dall'età di 3 anni e di almeno 15 kg di peso corporeo. nel decidere di iniziare il trattamento con o esposti per lungo tempo co-somministrato con basse dosi di ritonavir, attenta considerazione deve essere data la storia di trattamento per il singolo paziente e il tipo di mutazioni associate con diversi agenti. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 e 5. o esposti per lungo tempo co-somministrato con basse dosi di ritonavir è indicato in combinazione con altri medicinali antiretrovirali per il trattamento di pazienti con il virus dell'immunodeficienza umana (hiv-1) infezione.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. nel decidere di iniziare il trattamento con o esposti per lungo tempo in tale arte-esperto pazienti, genotipica test devono guidare l'uso di o esposti per lungo tempo (vedere sezioni 4. 2, 4. 3, 4. 4 e 5.

Deltyba Unione Europea - italiano - EMA (European Medicines Agency)

deltyba

otsuka novel products gmbh - delamanid - tubercolosi, resistente ai farmaci multiresistenti - antimicobatterici - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 e 5. dovrebbero essere prese in considerazione le linee guida ufficiali sull'uso appropriato degli agenti antibatterici..

Prezista Unione Europea - italiano - EMA (European Medicines Agency)

prezista

janssen-cilag international nv - darunavir - infezioni da hiv - antivirali per uso sistemico - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

LAUTER 20CPR EFF 5MG Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

lauter 20cpr eff 5mg

pensa pharma spa - domperidone - cpr effervescenti/solubili - "5 mg compresse effervescenti" 20 compresse